Login to Your Account



Clinic Roundup


Thursday, October 6, 2011
Halozyme Therapeutics Inc., of San Diego, began patient dosing in a Phase II trial with pegylated rHuPH20 (PEGPH20) in patients with Stage IV previously untreated pancreatic cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription